MeiraGTx Holdings (MGTX) Stock Analysis & AI Equity Report
MeiraGTx Holdings (MGTX) overview
MeiraGTx Holdings (MGTX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 81.4m and operating profit of USD -106m; the year-end share price was 7.95 USD and market capitalisation was USD 645m. MeiraGTx Holdings is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get MeiraGTx Holdings's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About MeiraGTx Holdings
MeiraGTx develops genetic medicines for inherited and other diseases, using targeted local delivery of genetic medicine candidates. Its programs include clinical-stage treatments for radiation-induced dry mouth, Parkinson’s disease, and retinal dystrophy. The company also develops gene regulation technology and provides internal manufacturing capabilities for viral vectors, plasmids, and quality-control testing to support its programs and third-party supply obligations.
Generate the MeiraGTx Holdings report
MeiraGTx Holdings is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for MeiraGTx Holdings and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on MeiraGTx Holdings
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.